Close Menu

Well, knock GTO over with a feather: we never thought we'd see the day that "RNA interference" made it into a Wall Street Journal headline. This article reports on recent results from Alnylam Pharmaceuticals' human trial for its RNAi-based drug for respiratory syncytial virus. The story quotes Alnylam CEO John Maraganore as saying, "This is really the first moonwalk for RNAi therapeutics." Michael Jackson would be so proud.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.